{"id":616,"date":"2024-09-11T13:57:45","date_gmt":"2024-09-11T13:57:45","guid":{"rendered":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/?page_id=616"},"modified":"2024-09-11T13:57:45","modified_gmt":"2024-09-11T13:57:45","slug":"personalizacion-de-tratamientos-oncologicos","status":"publish","type":"page","link":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/personalizacion-de-tratamientos-oncologicos\/","title":{"rendered":"Personalization of cancer treatments"},"content":{"rendered":"

Personalization of cancer treatments<\/h1>\n

Principal Investigator<\/b><\/h4>\n\n\n\n
<\/td>\nFernando Guti\u00e9rrez Nicol\u00e1s, PhD<\/strong><\/p>\n

Head of Research Unit, Specialist Physician in Hospital Pharmacy Area CHUC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Collaborating researchers<\/b><\/p>\n

    \n
  • Ruth Ramos D\u00edaz, PhD (Molecular Biologist, Head of the Genetics Section, Research Unit, CHUC)<\/span><\/li>\n
  • Mar\u00eda Micaela Vi\u00f1a, PhD (Hospital Pharmacist in the Onco-Hematology area, Head of the Hematology Section, Research Unit, CHUNSC)<\/span><\/li>\n
  • Sara Garc\u00eda, PhD (Hospital Pharmacist in the Onco-Hematology area, Head of the Immune-Mediated and Statistical Development Section, CHUC)<\/span><\/li>\n
  • Ivette Mourani (Molecular Biologist, Head of Chromatography Area and Data Manager)<\/span><\/li>\n
  • Juana Oramas, PhD (Head of the Medical Oncology Service, CHUC \u2013 Support to the Oncology Area)<\/span><\/li>\n
  • Mat\u00edas Llabr\u00e9s, PhD (Professor of Pharmaceutical Technology, ULL \u2013 development of clinical models)<\/span><\/li>\n<\/ul>\n

    PhD students and researchers in training<\/b><\/p>\n

      \n
    • Betel del Rosario, PhD (Doctoral Program in Health Sciences, ULL. Hospital Pharmacist in the Immune-Mediated Area, Head of the Oncology Section, CHUC)<\/span><\/li>\n<\/ul>\n

      Lines of research<\/b><\/p>\n

        \n
      1. Germline mutations in the individualization of treatments<\/b>. Identify genetic alterations that primarily affect the safety and effectiveness of treatments.<\/span><\/li>\n
      2. Somatic mutations in the individualization of cancer treatments<\/b>. Identify genetic alterations that affect the effectiveness of treatments.<\/span><\/li>\n
      3. Monitoring of plasma drug levels<\/b>. To highlight the clinical value of the therapeutic intervals of drugs by establishing their relationship with their efficacy and safety.\u00a0<\/span><\/li>\n
      4. Adherence to treatments<\/b>. To study the clinical consequences of a lack of adherence to pharmacological treatment and to analyze the conditions for it.<\/span><\/li>\n<\/ol>\n

        Funded projects<\/b><\/p>\n

          \n
        • Genetic fingerprinting and individualization of treatment in pediatric onco-hematological patients (PIFIISC22\/39). PI: Fernando Guti\u00e9rrez Nicol\u00e1s. Canary Islands Foundation Institute of Health Research of the Canary Islands, FIISC (2023-2024, \u20ac18,301.84)<\/span><\/li>\n
        • Clinical relevance of the UGT1A gene in Sacituzumab-Govitecan treatment for metastatic triple-negative breast cancer. PI: Fernando Guti\u00e9rrez Nicol\u00e1s. Canary Islands Health Research Institute Foundation, FIISC (2023-2025, \u20ac18,000)<\/span><\/li>\n
        • Pharmacokinetics of natalizumab in the treatment of MS. PI: Fernando Guti\u00e9rrez Nicol\u00e1s. Canary Islands Foundation Institute of Health Research of the Canary Islands, FIISC (2023-2025, \u20ac8,000)<\/span><\/li>\n<\/ul>\n

          Publications 2023<\/b><\/p>\n

            \n
          • Cantarelli L, Pestana Grafi\u00f1a D, Gonzalez Perez A, Garc\u00eda Gil S, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>, Ramos Santana E, Navarro D\u00e1vila MA, Otazo P\u00e9rez SM, Calzado G\u00f3mez G, Perez Reyes S, Nazco Casariego GJ. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice. <\/span>Ann Pharmacother<\/span><\/i>. 2023 Apr;57(4):416-424. DOI: 10.1177\/10600280221118402<\/span><\/li>\n
          • Del Rosario Garc\u00eda B, Vi\u00f1a Romero MM, Gonz\u00e1lez Rosa V, Alarc\u00f3n Payer C, Oliva Oliva L, Merino Alonso FJ, Nazco Casariego GJ, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>. Incorporation into the ITB, Dr. Guti\u00e9rrez F. UI-CHUC Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukaemia. <\/span>J Oncol Pharm Pract<\/span><\/i>. 2023 Sep 25:10781552231196130. DOI: 10.1177\/10781552231196130. Epub ahead of print<\/span><\/li>\n
          • Miarons M, Manzaneque Gord\u00f3n A, Riera P, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>; RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH). Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. <\/span>Oncologist<\/span><\/i>. 2023 May;28(5):e304-e308. DOI: 10.1093\/oncolo\/oyad077<\/span><\/li>\n
          • Morales-Arr\u00e1ez D, Ben\u00edtez-Zafra F, D\u00edaz-Flores F, Medina-Alonso MJ, Santiago LG, P\u00e9rez-P\u00e9rez V, <\/span>Guti\u00e9rrez-Nicol\u00e1s F, Hern\u00e1ndez-Guerra M<\/b>. A slowdown of hepatitis C diagnosis in high-prevalence groups and with decentralized diagnostic strategies during the COVID-19 pandemic. <\/span>Spanish Journal of Digestive Diseases<\/span><\/i>. 2023 Apr;115(4):175-180. DOI: 10.17235\/reed.2022.8412\/2021<\/span><\/li>\n<\/ul>\n

            Other representative publications from recent years<\/b><\/p>\n

              \n
            • Cantarelli L, Carrillo Palau M, <\/span>Hernandez Guerra M<\/b>, Nazco Casariego GJ, <\/span>Gutierrez Nicol\u00e1s F<\/b>. Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. <\/span>Med Clin (Barc)<\/span><\/i>. 2023 Feb 10;160(3):107-112. DOI: 10.1016\/j.medcli.2022.05.008<\/span><\/li>\n
            • Del Rosario Garc\u00eda B, Gonz\u00e1lez Garc\u00eda I, Vi\u00f1a Romero MM, Gonz\u00e1lez Garc\u00eda J, Ramos D\u00edaz R, Mourani Padr\u00f3n I, Lakhwani Lakhwani S, Nazco Casariego GJ, <\/span>Guti\u00e9rrez Nicol\u00e1s F<\/b>. Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions. <\/span>J Oncol Pharm Pract<\/span><\/i>. 2021 Oct 18:10781552211052535. DOI: 10.1177\/10781552211052535<\/span><\/li>\n
            • Vi\u00f1a-Romero MM, Ramos-Diaz R, Mourani-Padron I, Gonzalez-Mendez H, Gonzalez-Cruz M, Nazco-Casariego GJ, Merino-Alonso JF, Diaz-Vera J, <\/span>Guti\u00e9rrez-Nicol\u00e1s F<\/b>. Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials. <\/span>In Vivo<\/span><\/i>. 2020;34(5):2419-2421. DOI: 10.21873\/invivo.12055<\/span><\/li>\n
            • Vi\u00f1a-Romero MM, Ramos D\u00edaz R, Gonz\u00e1lez Garc\u00eda J, Nazco-Casariego G, D\u00edaz-Vera J, <\/span>Guti\u00e9rrez-Nicol\u00e1s F<\/b>. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials. <\/span>J Oncol Pharm Pract<\/span><\/i>. 2021 Jul;27(5):1102-1105. DOI:10.1177\/1078155220950001<\/span><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

              Personalized Cancer Treatments. Principal Investigator: Fernando Guti\u00e9rrez Nicol\u00e1s, PhD, Head of Research Unit, Specialist Physician, Hospital Pharmacy, CHUC. Collaborating Investigators: Ruth Ramos D\u00edaz, PhD (Molecular Biologist, Head of the Genetics Section, Research Unit, CHUC); Mar\u00eda Micaela Vi\u00f1a, PhD (Hospital Pharmacist, Onco-Hematology Area, Head of the Hematology Section, Unit\u2026<\/p>","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-616","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/pages\/616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/comments?post=616"}],"version-history":[{"count":1,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/pages\/616\/revisions"}],"predecessor-version":[{"id":617,"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/pages\/616\/revisions\/617"}],"wp:attachment":[{"href":"https:\/\/www.ull.es\/institutos\/instituto-tecnologias-biomedicas\/en\/wp-json\/wp\/v2\/media?parent=616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}